Literature DB >> 12120442

Cytomegalovirus infections.

Mohamad Khoshnevis1, Stephen K Tyring.   

Abstract

Over the past two decades, there has been an escalation in the number of patients undergoing immunosuppressive therapy following solid organ or bone marrow transplantation, as well as a dramatic increase in the incidence of AIDS. As a result, human cytomegalovirus (HCMV)--once considered a neonatal disease--has captured great interest and importance as a major pathogen in both immunocompromised and immunocompetent patients. Like other members of herpesviridae family, HCMV establishes latency in myeloid lineage cells with potential for reactivation. The natural history of HCMV infection can be divided into primary infection, latency, and reinfection. This review article briefly discusses the molecular pathogenesis of HCMV, then focuses on the clinical picture of this disease, with emphasis on the skin pathology. Diagnostic methods and treatments are also discussed.

Entities:  

Mesh:

Year:  2002        PMID: 12120442     DOI: 10.1016/s0733-8635(01)00007-9

Source DB:  PubMed          Journal:  Dermatol Clin        ISSN: 0733-8635            Impact factor:   3.478


  10 in total

1.  Human cytomegalovirus-encoded miR-US4-1 promotes cell apoptosis and benefits discharge of infectious virus particles by targeting QARS.

Authors:  Yaozhong Shao; Ying Qi; Yujing Huang; Zhongyang Liu; Yanping Ma; Xin Guo; Shujuan Jiang; Zhengrong Sun; Qiang Ruan
Journal:  J Biosci       Date:  2016-06       Impact factor: 1.826

2.  Cyclophilin A is required for efficient human cytomegalovirus DNA replication and reactivation.

Authors:  Lisa R Keyes; Mariana G Bego; Melisa Soland; Stephen St Jeor
Journal:  J Gen Virol       Date:  2012-01-13       Impact factor: 3.891

3.  Expression of cutaneous lymphocyte-associated antigen and E-selectin ligand by circulating human memory CD4+ T lymphocytes specific for herpes simplex virus type 2.

Authors:  Julio C González; William W Kwok; Anna Wald; Christopher L McClurkan; Jay Huang; David M Koelle
Journal:  J Infect Dis       Date:  2004-12-15       Impact factor: 5.226

4.  Human cytomegalovirus miR-US5-1 inhibits viral replication by targeting Geminin mRNA.

Authors:  Shujuan Jiang; Yujing Huang; Ying Qi; Rong He; Zhongyang Liu; Yanping Ma; Xin Guo; Yaozhong Shao; Zhengrong Sun; Qiang Ruan
Journal:  Virol Sin       Date:  2017-10-31       Impact factor: 4.327

5.  Human Cytomegalovirus Influences Host circRNA Transcriptions during Productive Infection.

Authors:  Jingui Deng; Yujing Huang; Qing Wang; Jianming Li; Yanping Ma; Ying Qi; Zhongyang Liu; Yibo Li; Qiang Ruan
Journal:  Virol Sin       Date:  2020-08-05       Impact factor: 4.327

6.  Down-regulation of human cytomegalovirus UL138, a novel latency-associated determinant, by hcmv-miR-UL36.

Authors:  Yujing Huang; Ying Qi; Yanping Ma; Rong He; Yaohua Ji; Zhengrong Sun; Qiang Ruan
Journal:  J Biosci       Date:  2013-09       Impact factor: 1.826

7.  Fragment of tegument protein pp65 of human cytomegalovirus induces autoantibodies in BALB/c mice.

Authors:  Ao-Ho Hsieh; Yí-Jyun Jhou; Chung-Ting Liang; Mingi Chang; Shih-Lien Wang
Journal:  Arthritis Res Ther       Date:  2011-10-11       Impact factor: 5.156

8.  Different expression pattern of human cytomegalovirus-encoded microRNAs in circulation from virus latency to reactivation.

Authors:  Wanqing Zhou; Cheng Wang; Meng Ding; Yuying Bian; Yujie Zhong; Han Shen; Junjun Wang; Chen-Yu Zhang; Chunni Zhang
Journal:  J Transl Med       Date:  2020-12-09       Impact factor: 5.531

9.  Vitamin D3 Suppresses Human Cytomegalovirus-Induced Vascular Endothelial Apoptosis via Rectification of Paradoxical m6A Modification of Mitochondrial Calcium Uniporter mRNA, Which Is Regulated by METTL3 and YTHDF3.

Authors:  Wenbo Zhu; Hongbo Zhang; Shao Wang
Journal:  Front Microbiol       Date:  2022-03-11       Impact factor: 5.640

10.  Skin manifestations of herpesvirus infections.

Authors:  John F Toney
Journal:  Curr Infect Dis Rep       Date:  2005-09       Impact factor: 3.663

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.